HPV-induced carcinogenesis of the uterine cervix is associated with reduced serum ATRA level.

2.50
Hdl Handle:
http://hdl.handle.net/10146/54413
Title:
HPV-induced carcinogenesis of the uterine cervix is associated with reduced serum ATRA level.
Authors:
Berlin Grace, V. M.; Niranjali Devaraj, S.; Radhakrishnan Pillai, M.; Devaraj, Halagowder
Abstract:
OBJECTIVE: In uterine cervical cancer, certain oncogenic HPV types are considered as key etiologic factor. But the progression of HPV associated cervical precancerous lesions depends on many other factors such as oncogenes, immune system, anti-viral factors etc. This study is therefore focused on the effect of an important dietary anti-viral factor called All Trans Retinoic Acid (ATRA) on the development of HPV associated cervical cancer as it is found higher in poor socioeconomic people. METHOD: We analyzed a total population of 130 including control subjects who have no complaints of uterine cervical lesions and the HPV-6/11, 16/18 infected cases of low grade squamous intraepithelial lesions [SIL], high grade squamous intraepithelial lesions [HSIL], and invasive cancers, for serum ATRA level. This study also focused to find out the association of serum ATRA level with the proliferation status in terms of proliferating cell nuclear antigen (PCNA) expression as it is an anti-proliferation agent and with the grades of cervical lesions, using SPSS statistical package. RESULTS: The results showed a highly significant negative association for serum ATRA level with different stages of cervical lesions (F = 3.305; P = 0.000) by one-way ANOVA and with intensity of PCNA expression (r = -0.825; P < 0.01) by Pearson's correlation test. A highly significant association was observed for the PCNA expression with the grades of cervical lesions too (F = 37.89; P = 0.000). Further, we found from our data that all the invasive cancer cases were infected with HPV-16/18 and none with HPV-6/11. Hence, we analyzed the association of serum ATRA level with HPV-16/18 infected preinvasive cases in developing invasiveness, by Fisher's Exact Test, using Graph Pad Prism as shown in Table 1. The results show an odds ratio (OR) of 36.93 and a relative risk (RR) of 4.99 with an 95% interval being 2.896 to 8.603, which is significant at the level of P = 0.0001 for the reduced [<0.6 mug/ml] serum ATRA level in developing invasive cancer in HPV-16/18 infected preinvasive cases. CONCLUSION: All these results suggest that the serum ATRA level highly influences the progression of cervical lesions to invasive cancer and can be therefore aimed as a marker for progression in combination with HPV-16/18, which helps to enhance the modalities of therapy towards cost effectiveness.
Citation:
Gynecol. Oncol. 2006, 103 (1):113-119
Journal:
Gynecologic oncology
Issue Date:
Oct-2006
URI:
http://hdl.handle.net/10146/54413
DOI:
10.1016/j.ygyno.2006.01.057
PubMed ID:
16554086
Additional Links:
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6WG6-4JJ2BG7-1&_user=1843694&_rdoc=1&_fmt=&_orig=search&_sort=d&view=c&_acct=C000055040&_version=1&_urlVersion=0&_userid=1843694&md5=a5691f51fc1a6146d941c170a1c88fea
Type:
Article
Language:
en
Description:
Dietary modulation of cancer & cancer biomarkers Dietary item or component studied:ATRA (all-trans-retinol)Outcome studied (cancer or cancer biomarker):Cervical cancerSystem used (in vitro, animals, humans):humansStudy design (if human):case-controlStudy size (if human):20 controls, 20 low grade squamous intraepithelial lesions, 30 high grade squamous intraepithelial lesions, 60 invasive cancerTissue/biological material/sample size:10-15 sections of 10μm uterine, blood samplesMode of exposure (if in vivo):normal diet (not intervention)Impact on outcome (including dose-response):control ATRA level 0.6183+/-0.024LSIL ATRA level 0.5466+/-0.095, 9 people had HPV6, 11 had HPV11,HSIL ATRA level 0.4930+/-0.16, 6 had HPV6, 2 had HPV11,14 had HPV16, 8 had HPV18INVASIVE ATRA level 0.3097+/-0.077, 42 had HPV16, 18 had HPV18. KEYWORDS CLASSIFICATION: analysis;Adult;biomarkers of exposure & effect: field studies;biomarkers of exposure & effect: validation;biosynthesis;blood;Biotechnology;classification;complications;Cell Growth Processes;Cell Transformation,Viral;Cervical Intraepithelial Neoplasia;dietary modulation of cancer & cancer biomarkers;dietary modulation of carcinogenesis-related pathways;Female;genetics;Humans;India;Middle Aged;Neoplasm Staging;pathology;physiology;Papillomaviridae;Papillomavirus Infections;Polymerase Chain Reaction;Proliferating Cell Nuclear Antigen;Research;therapy;Tretinoin;Uterine Cervical Neoplasms;validation;virology;field studies.
ISSN:
0090-8258
Appears in Collections:
Articles with annotation

Full metadata record

DC FieldValue Language
dc.contributor.authorBerlin Grace, V. M.-
dc.contributor.authorNiranjali Devaraj, S.-
dc.contributor.authorRadhakrishnan Pillai, M.-
dc.contributor.authorDevaraj, Halagowder-
dc.date.accessioned2009-03-12T08:51:57Z-
dc.date.available2009-03-12T08:51:57Z-
dc.date.issued2006-10-
dc.identifier.citationGynecol. Oncol. 2006, 103 (1):113-119en
dc.identifier.issn0090-8258-
dc.identifier.pmid16554086-
dc.identifier.doi10.1016/j.ygyno.2006.01.057-
dc.identifier.urihttp://hdl.handle.net/10146/54413-
dc.descriptionDietary modulation of cancer & cancer biomarkers Dietary item or component studied:ATRA (all-trans-retinol)Outcome studied (cancer or cancer biomarker):Cervical cancerSystem used (in vitro, animals, humans):humansStudy design (if human):case-controlStudy size (if human):20 controls, 20 low grade squamous intraepithelial lesions, 30 high grade squamous intraepithelial lesions, 60 invasive cancerTissue/biological material/sample size:10-15 sections of 10μm uterine, blood samplesMode of exposure (if in vivo):normal diet (not intervention)Impact on outcome (including dose-response):control ATRA level 0.6183+/-0.024LSIL ATRA level 0.5466+/-0.095, 9 people had HPV6, 11 had HPV11,HSIL ATRA level 0.4930+/-0.16, 6 had HPV6, 2 had HPV11,14 had HPV16, 8 had HPV18INVASIVE ATRA level 0.3097+/-0.077, 42 had HPV16, 18 had HPV18. KEYWORDS CLASSIFICATION: analysis;Adult;biomarkers of exposure & effect: field studies;biomarkers of exposure & effect: validation;biosynthesis;blood;Biotechnology;classification;complications;Cell Growth Processes;Cell Transformation,Viral;Cervical Intraepithelial Neoplasia;dietary modulation of cancer & cancer biomarkers;dietary modulation of carcinogenesis-related pathways;Female;genetics;Humans;India;Middle Aged;Neoplasm Staging;pathology;physiology;Papillomaviridae;Papillomavirus Infections;Polymerase Chain Reaction;Proliferating Cell Nuclear Antigen;Research;therapy;Tretinoin;Uterine Cervical Neoplasms;validation;virology;field studies.en
dc.description.abstractOBJECTIVE: In uterine cervical cancer, certain oncogenic HPV types are considered as key etiologic factor. But the progression of HPV associated cervical precancerous lesions depends on many other factors such as oncogenes, immune system, anti-viral factors etc. This study is therefore focused on the effect of an important dietary anti-viral factor called All Trans Retinoic Acid (ATRA) on the development of HPV associated cervical cancer as it is found higher in poor socioeconomic people. METHOD: We analyzed a total population of 130 including control subjects who have no complaints of uterine cervical lesions and the HPV-6/11, 16/18 infected cases of low grade squamous intraepithelial lesions [SIL], high grade squamous intraepithelial lesions [HSIL], and invasive cancers, for serum ATRA level. This study also focused to find out the association of serum ATRA level with the proliferation status in terms of proliferating cell nuclear antigen (PCNA) expression as it is an anti-proliferation agent and with the grades of cervical lesions, using SPSS statistical package. RESULTS: The results showed a highly significant negative association for serum ATRA level with different stages of cervical lesions (F = 3.305; P = 0.000) by one-way ANOVA and with intensity of PCNA expression (r = -0.825; P < 0.01) by Pearson's correlation test. A highly significant association was observed for the PCNA expression with the grades of cervical lesions too (F = 37.89; P = 0.000). Further, we found from our data that all the invasive cancer cases were infected with HPV-16/18 and none with HPV-6/11. Hence, we analyzed the association of serum ATRA level with HPV-16/18 infected preinvasive cases in developing invasiveness, by Fisher's Exact Test, using Graph Pad Prism as shown in Table 1. The results show an odds ratio (OR) of 36.93 and a relative risk (RR) of 4.99 with an 95% interval being 2.896 to 8.603, which is significant at the level of P = 0.0001 for the reduced [<0.6 mug/ml] serum ATRA level in developing invasive cancer in HPV-16/18 infected preinvasive cases. CONCLUSION: All these results suggest that the serum ATRA level highly influences the progression of cervical lesions to invasive cancer and can be therefore aimed as a marker for progression in combination with HPV-16/18, which helps to enhance the modalities of therapy towards cost effectiveness.en
dc.language.isoenen
dc.relation.urlhttp://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6WG6-4JJ2BG7-1&_user=1843694&_rdoc=1&_fmt=&_orig=search&_sort=d&view=c&_acct=C000055040&_version=1&_urlVersion=0&_userid=1843694&md5=a5691f51fc1a6146d941c170a1c88feaen
dc.subjectSerum ATRA levelen
dc.subjectProgression and diagnostic markeren
dc.subjectHPV associated cervical lesionsen
dc.subjectPCNA expressionen
dc.subject.meshAdult-
dc.subject.meshCell Growth Processes-
dc.subject.meshCell Transformation, Viral-
dc.subject.meshCervical Intraepithelial Neoplasia-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshMiddle Aged-
dc.subject.meshNeoplasm Staging-
dc.subject.meshPapillomaviridae-
dc.subject.meshPapillomavirus Infections-
dc.subject.meshPolymerase Chain Reaction-
dc.subject.meshProliferating Cell Nuclear Antigen-
dc.subject.meshTretinoin-
dc.subject.meshUterine Cervical Neoplasms-
dc.titleHPV-induced carcinogenesis of the uterine cervix is associated with reduced serum ATRA level.en
dc.typeArticleen
dc.identifier.journalGynecologic oncologyen
All Items in ECNIS-NIOM are protected by copyright, with all rights reserved, unless otherwise indicated.